Online Interactive Workshop

Use NEXT GENERATION technology in medical laboratory quality/risk management to project clinical savings throughout the health care system - a test case to study HbA1c.

Premiere

Special!

What are the clinical costs and risks to patients and healthcare systems of errors in HbA1c results that mislead doctors to either:
[A] mis-classify patient as low risk instead of high risk of diabetes, or
[B] think that patients are improving or not improving when the opposite is actually true?

Validate the effectiveness of existing quality control processes to detect medically-significant error. Prepare to be shocked by this realtime demo!

Regular Multi-Lab Workshop Price $497.00 Introductory sale $124.25

Use NEXT GENERATION technology in medical laboratory quality/risk management to project clinical savings throughout the health care system - a test case to study HbA1c.

Sign up now for the chance to submit your data!

Who Will BENEFIT?

Laboratory Medical Directors, Technical Managers

who want to meet compliance guidelines, save time & costs
and provide guidance to all staff

looking for cost savings and improvements in clinical care

Healthcare Institutions,

Regional Programs

seeking consistent assurance of acceptable patient risk, at routine review and if the method was to fail acceptable risk criteria.

Laboratory Consultants,

Inspectors & Staff

This is a cross-discipline workshop to look at this very critical test from many different perspectives

Each laboratory can submit data for up to five instruments and will receive detailed reports. All participants will see summary reports of all instruments by code.

This online interactive workshop will consist primarily of brief videos that you can watch at your convenience, case studies with discussion forums and surveys. Each of these will be designed for your particular interests and to get feedback from each participant group.

• to estimate the clinical costs to patients and healthcare systems of errors in HbA1c results that mislead doctors to either [A] mis-classify patient as low risk instead of high risk, or vice-versa, or [B] think that the patient is improving or not improving when the opposite is actually true;
• to preview new CatalystQC™ software service from AWEsome Numbers Inc., employing the concepts and algorithms of Mathematically-OptimiZed Risk Evaluation™ (M.O.R.E.™) to determine the number, clinical costs and measurement uncertainty of medically significant errors reported from each participating laboratory in January 2019;
• to evaluate the effectiveness of existing quality control process by quantifying the number and clinical cost of errors that would be reported if each instrument was to fail
• to compare the clinical and in-lab costs with existing quality control processes to M.O.R.E. Quality strategies selected by CatalystQC™ to meet acceptable risk;
• to discuss potential benefits of, and roadblocks to, automated statistical quality driven by Mathematically-OptimiZed Risk Evaluation™.

Workshop OBJECTIVES

Team LEADERS

CatalystQC™ is a Laboratory Director/Manager's real-time guide:

• simplifies implementation of medical laboratory best practice,
• validates QC process effectiveness and staff competency,
• saves money and resources in clinical and laboratory services.

Using our NEXT GENERATION Technology

CatalystQC™ is our cloud-based software platform that provides a standardized quality and risk evaluation approach for all of the key roles in medical labs or health-care organizations. Track and compare the performance of all your labs with our easy to use and easy to understand reports and dashboards. CatalystQC™ automates many of the tedious, time consuming tasks in Statistical QC, making it much easier to manage QC and Risk.

M.O.R.E.™ Quality is AWEsome Number’s next generation Statistical Quality Control and Risk Evaluation technology. It provides a "quality manager-in-a-box", calculating the required metrics, statistics and suggested actions for effective quality control and risk evaluation. M.O.R.E.™ Quality improves your methods and eliminates almost all statistical, analytical laboratory error. It is the core technology for our CatalystQC™ software.

GET M.O.R.E. VALUE while lowering QC COSTS

Laboratory Director / Manager's Overview Report

Risk metrics reveal numbers, cost, measurement uncertainty & QC effectiveness

This section of the report will enable you to know where to focus efforts to improve patient care and reduce clinical costs.

1. monitor all work performed in the laboratory to determine that clinically relevant information is being generated

The Laboratory Director's Overview report provides an overview of ability to meet ISO 15189 requirements and guides action to reduce risk and cost.

4. design quality control procedures that verify the attainment of the intended quality of results.

2. provide effective leadership of the medical laboratory service, including budget planning and financial interpretation of examination results

3. define the performance requirements for the measurement uncertainty of each measurement procedure and regularly review estimates of measurement uncertainty.

The laboratory director shall:

The laboratory shall:

Each QC Process PASSes if it is verified effective to alert staff immediately if acceptable risk levels defined in the laboratory policy become unacceptable.

QC samples PASS Measurement Uncertainty (MU) if the reported range of results, with biological plus analytical variation, includes the True Value defined for that sample

QC samples PASS the acceptable average cost of error defined in the quality policy manual - Note differences in total clinical cost / QC sample

Risk-Based-Quality (R-B-Q) Grades(c) A, B, C, & D PASS the acceptable number and cost of error defined in the quality policy manual

The Laboratory Director's Overview Report also shows potential savings in both clinical and laboratory

costs - if each method was to fail acceptable risk criteria for daily QC.

CatalystQC designs a full QC Strategy verified to meet acceptable number of errors per failure event and compares simulated failure to existing QC process design.

This section of the report presents potential clinical savings if the method fails once, plus annual savings for in-laboratory costs to test & review QC samples.

PREVIOUS Studies

We concluded that the calculated risk level is generally not accepted in healthcare. Adjustment of these procedures is mandatory.

Mathematically-OptimiZed Risk Evaluation™ detects laboratory risks that are missed by commonly used statistical QC.

Poster AACC 2014

Evaluation of Quality OptimiZer™ software to simplify application of CLSI EP 23-A, minimize patient risk and reduce clinical cost

The M.O.R.E. method increases the effectiveness of the QC process and its ability to reduce the number of MURs (medically-unreliable results)

It also alerts the laboratorian immediately when the analytical process changes enough to allow more than the acceptable number of MURs to be released. .

Quality OptimiZer reports satisfied EP 23-A recommendations:.
- ensures test result quality is appropriate for clinical use;

- provides suggestions on the frequency of QC sample procedures to have a high probability to detect a stated medically allowable error;

- at the least, provides the ability to check if QC procedures can detect medically allowable error.

Zoe Brooks, Raymond Gerz, Nathalie Lepage, David Plaut

Poster ASCLS 2016
Acceptability of Current Patient Risk

Brooks, ZC, El Sharkawy, RM MD, et al

Poster ASCLS 2016

Mathematically-OptimiZed Risk Evaluation™

Kim A. Przekop, Zoe C. Brooks